AstraZeneca to sell anti-psychotic medicine rights in Europe and Russia for $239m

This article was originally published here

Under the deal, Cheplapharm will acquire the commercial rights of Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release). The compound patent protection for Seroquel

The post AstraZeneca to sell anti-psychotic medicine rights in Europe and Russia for $239m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply